FY2025 EPS Estimates for Perrigo Lifted by Zacks Research

Perrigo Company plc (NYSE:PRGO) – Equities researchers at Zacks Research increased their FY2025 earnings per share (EPS) estimates for shares of Perrigo in a research note issued to investors on Monday, February 16th. Zacks Research analyst Team now anticipates that the company will earn $2.77 per share for the year, up from their prior forecast of $2.76. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q4 2025 earnings at $0.80 EPS, FY2026 earnings at $3.00 EPS, Q3 2027 earnings at $0.81 EPS, Q4 2027 earnings at $0.84 EPS and FY2027 earnings at $3.18 EPS.

Several other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. decreased their price objective on Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Wall Street Zen cut Perrigo from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Canaccord Genuity Group decreased their target price on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a research note on Monday, December 22nd. Finally, Jefferies Financial Group lowered their price objective on shares of Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a research note on Monday, October 27th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Perrigo presently has a consensus rating of “Hold” and a consensus price target of $20.33.

Perrigo Stock Up 1.1%

Perrigo stock opened at $14.61 on Thursday. The company has a current ratio of 2.51, a quick ratio of 1.44 and a debt-to-equity ratio of 0.81. Perrigo has a 1-year low of $12.17 and a 1-year high of $30.93. The company has a fifty day simple moving average of $14.23 and a 200 day simple moving average of $17.92. The company has a market cap of $2.01 billion, a P/E ratio of -38.43, a price-to-earnings-growth ratio of 1.30 and a beta of 0.39.

Institutional Trading of Perrigo

Several hedge funds and other institutional investors have recently bought and sold shares of the business. State of Michigan Retirement System grew its position in Perrigo by 1.2% during the second quarter. State of Michigan Retirement System now owns 33,058 shares of the company’s stock worth $883,000 after buying an additional 400 shares in the last quarter. Amundi boosted its holdings in shares of Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares in the last quarter. Slocum Gordon & Co LLP raised its stake in Perrigo by 1.1% during the third quarter. Slocum Gordon & Co LLP now owns 53,253 shares of the company’s stock worth $1,186,000 after acquiring an additional 602 shares in the last quarter. Hantz Financial Services Inc. boosted its position in Perrigo by 101.0% in the second quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock valued at $33,000 after buying an additional 620 shares in the last quarter. Finally, Kestra Investment Management LLC increased its holdings in Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after purchasing an additional 642 shares in the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.